AGIOS PHARMACEUTICALS, INC. Deferred Tax Liabilities, Property, Plant and Equipment
AGIOS PHARMACEUTICALS, INC. (AGIO) had Deferred Tax Liabilities, Property, Plant and Equipment of $418.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment · last filed 2026-02-12
- 2025-12-31: Deferred Tax Liabilities, Property, Plant and Equipment $418.00K.
- 2024-12-31: Deferred Tax Liabilities, Property, Plant and Equipment $1.19M.
- 2023-12-31: Deferred Tax Liabilities, Property, Plant and Equipment $1.99M.
- 2022-12-31: Deferred Tax Liabilities, Property, Plant and Equipment $3.77M.
| Period end | Deferred Tax Liabilities, Property, Plant and Equipment |
|---|---|
| 2025-12-31 | $418.00K 10-K · filed 2026-02-12 |
| 2024-12-31 | $1.19M 10-K · filed 2026-02-12 |
| 2023-12-31 | $1.99M 10-K · filed 2025-02-13 |
| 2022-12-31 | $3.77M 10-K · filed 2024-02-15 |
| 2021-12-31 | $3.17M 10-K · filed 2023-02-23 |
| 2020-12-31 | $4.00M 10-K · filed 2022-02-24 |
| 2019-12-31 | $2.61M 10-K · filed 2021-02-25 |
| 2018-12-31 | $3.57M 10-K · filed 2020-02-19 |
| 2017-12-31 | $4.55M 10-K · filed 2019-02-14 |
| 2016-12-31 | $8.41M 10-K · filed 2018-02-14 |
| 2015-12-31 | $6.97M 10-K · filed 2017-02-16 |
| 2014-12-31 | $1.53M 10-K · filed 2016-02-26 |
| 2013-12-31 | $444.00K 10-K · filed 2015-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |